Literature DB >> 7104178

Predictive indices for chlorpromazine therapy in schizophrenics.

P A Dixon, E Oforah, R Makanjuola.   

Abstract

1 Response to chlorpromazine therapy was studied in 24 schizophrenics and 75% reduction in Brief Psychiatric Rating scale (BPRS) within 4 weeks of treatment was taken to indicate good response. 2 Test oral dose of CPZ (200 mg) was administered and serial blood samples and total urine excreted in 6 h were taken for analyses of CPZ and its metabolites. 3 Area under the plasma time curve (AUC) showed an inverted U-shaped relationship with % reduction in BPRS. 4 Three groups of patients were identified, responders, l- and h-group non-responders. 5 l- and h-groups respond on further treatment with haloperidol (30 mg daily) and ECT respectively. 6 Responders showed threshold metabolic molar fraction MMFHO-CPZ greater than or equal to 3.0 x 10(-5) and MMFHO-CPZ/MMFCPZ-SO greater than 1.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104178      PMCID: PMC1427744          DOI: 10.1111/j.1365-2125.1982.tb01973.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Cerebrospinal fluid levels of chlorpromazine and it metabolites in schizophrenia.

Authors:  S Axelsson; S Jönsson; L Nordgren
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1975-12-31

2.  Effects of mode of management on plasma chlorpromazine in psychiatric patients.

Authors:  L Rivera-Calimlim; L Castañeda; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

3.  The possible role of metabolites in therapeutic response to chlorpromazine treatment.

Authors:  G Sakalis; T L Chan; S Gershon; S Park
Journal:  Psychopharmacologia       Date:  1973-09-28

4.  Physiologic and clinical effects of chlorpromazine and their relationship to plasma level.

Authors:  G Sakalis; S H Curry; G P Mould; M H Lader
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

5.  Chlorpromazine plasma levels and effects.

Authors:  S H Curry; J H Marshall; J M Davis; D S Janowsky
Journal:  Arch Gen Psychiatry       Date:  1970-04

6.  Prediction of response to chlorpromazine treatment in schizophrenics.

Authors:  Y Sakurai; T Nakahara; R Takahashi
Journal:  Psychopharmacologia       Date:  1975-10-31

7.  Correlation between plasma chlorpromazine and its metabolites and clinical ratings in patients with acute relapse of schizophrenic and paranoid psychosis.

Authors:  O T Phillipson; J M McKeown; J Baker; A F Healey
Journal:  Br J Psychiatry       Date:  1977-08       Impact factor: 9.319

8.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1976-02       Impact factor: 18.112

9.  Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs.

Authors:  A S Horn; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1971-10       Impact factor: 11.205

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.